Biblio
Unsupervised meta-clustering identifies risk clusters in acute myeloid leukemia based on clinical and genetic profiles. Commun Med (Lond). 2023;3(1):68.
Reduced intensity versus non-myeloablative conditioning regimen for haploidentical transplantation and post-transplantation cyclophosphamide in complete remission acute myeloid leukemia: a study from the ALWP of the EBMT. Bone Marrow Transplant. 2022.
Pre-transplant weight loss predicts inferior outcome after allogeneic stem cell transplantation in patients with myelodysplastic syndrome. Oncotarget. 2015.
Pretransplant Metabolic Distress Predicts Relapse of Acute Myeloid Leukemia After Allogeneic Stem Cell Transplantation. Transplantation. 2014.
Post-Transplant Cyclophosphamide for Graft vs Host Disease Prophylaxis in Multiple Myeloma Patients Who Underwent Allogeneic Hematopoietic Cell Transplantation: First Comparison by Donor Type: A Study from the Chronic Malignancies Working Party of the EBM. Transplant Cell Ther. 2021.
Outcome of patients with abnl(17p) acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation. Blood. 2014.
Mesenchymal Stromal Cells for Treatment of Acute Steroid-Refractory GvHD: Clinical Responses and Long-Term Outcome. Stem Cells. 2015.
Long-term survival benefit after allogeneic hematopoietic cell transplantation in chronic myelomonocytic leukemia. Biol Blood Marrow Transplant. 2020.
Long-term outcome of second allogeneic hematopoietic stem cell transplantation (HSCT2) for primary graft failure in patients with acute leukemia in remission: A study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marr. Bone Marrow Transplant. 2023.
In-vitro detection of Candida and Aspergillus antigen in parenteral nutrition and fixed combinations of piperacillin-tazobactam. Mycoses. 2018.
. HLA mismatched donors in patients with myelodysplastic syndrome: an EBMT registry analysis. Biol Blood Marrow Transplant. 2018.
High-Dose Cytarabine Consolidation With or Without Additional Amsacrine and Mitoxantrone in Acute Myeloid Leukemia: Results of the Prospective Randomized AML2003 Trial. J Clin Oncol. 2013.
Graft-versus-host-disease prophylaxis with ATG or PTCY in patients with lymphoproliferative disorders undergoing reduced intensity conditioning regimen HCT from one antigen mismatched unrelated donor. Bone Marrow Transplant. 2024.
Fludarabine-treosulfan versus fludarabine-melphalan or busulfan-cyclophosphamide conditioning in older AML or MDS patients - A clinical trial to registry data comparison. Bone Marrow Transplant. 2024.